Evolv (EVLV), maker of AI-driven security screening products, reported strong revenue growth and improved cash flow, while revising its FY26 guidance upward. Despite facing gross margin pressure from a higher mix of purchase subscriptions and product upgrades, the company is offsetting costs with price increases and manufacturing improvements. Evolv added 70 new customers and sees growth potential with its Gen2 and eXpedite products. Management targets $500 million revenue and 25% adjusted EBITDA margins by 2031, highlighting the company's competitive edge in AI technology and a large addressable market.
The Canadian ALS Society has renewed funding from TD Bank to expand its national genetics strategy for ALS, improving access to genetic information, counseling, and care for those affected or at risk. This initiative builds on a pilot project that cr...
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
Glider has introduced a global investing platform for tokenized stocks that operates permissionlessly, bypassing the SEC's Tokenized Securities Venues (TSVs) which 50 public companies recently rejected. Backed by major investors like a16z and Coinbas...
BofA Securities raised its price target for Royal Caribbean Group to $365, citing strong booking volumes and the company’s goal of adjusted earnings per share around $20 by 2027. The cruise operator expects 4.5% capacity growth next year and has repo...
